Patent intelligence · US
US 9682969
Phthalazinone compounds and methods for the treatment of cystic fibrosis
Phthalazinone compounds and methods for the treatment of cystic fibrosis
Patent details — US 9682969
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 20, 2017
- Expiration
- Jun 15, 2037
- Applicant
- Flatley Discovery Lab, LLC
- Claims
- 20
- CPC classes
- A61K, A61K31/38, A61K31/4245, A61K31/443
Quick answer
US 9682969 (Phthalazinone compounds and methods for the treatment of cystic fibrosis) is held by Flatley Discovery Lab, LLC. Status: granted. Granted Jun 20, 2017. Expires Jun 15, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Flatley Discovery Lab, LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/38, A61K31/4245, A61K31/443, A61K31/47, A61K31/502
More from Flatley Discovery Lab, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 9682969?
US 9682969 (Phthalazinone compounds and methods for the treatment of cystic fibrosis) is held by Flatley Discovery Lab, LLC. Status: granted. Granted Jun 20, 2017. Expires Jun 15, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9682969?
Flatley Discovery Lab, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 9682969 expire?
Our index shows an expiration date of Jun 15, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.